全球 3D 列印药物市场规模、份额、成长分析，依技术类型（喷墨列印、熔融沈积建模）、按应用（骨科、神经科）- 2024-2031 年产业预测

Global 3D Printed Drugs Market Size, Share, Growth Analysis, By Technology Type(Inkjet Printing, Fused Deposition Modeling), By Application(Orthopaedic, Neurology) - Industry Forecast 2024-2031

出版日期: 2024年04月06日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022 年，全球 3D 列印药物市场规模为 8,491 万美元，预计将从 2023 年的 9,850 万美元成长到 2031 年的 3.2291 亿美元，预测期内（2024-2031 年）复合年增长率为 16%。

在製药业中，3D列印药品市场正在全球快速扩张。越来越多的药物配方可以使用3D列印技术来定制，这可以提高药物疗效、减少副作用并提供个人化剂量。 3D 列印的方法是沉积连续的材料层来创建三维物体。在药物生产中，这需要将精确的药物剂量列印到基材上。市场以北美、欧洲和亚太地区为主。市场的扩张可归因于对定製药物的需求不断增长、技术改进以及 3D 列印提供准确剂量和尽量减少负面影响的能力。 3D 列印药物市场旨在提供一种新颖且富有创意的药物生产方法，以改善患者的治疗效果并降低医疗成本。由于在药物製造中使用 3D 列印技术，药物可以按需生产，从而减少浪费并提高设计自由度。降低医疗成本的需求、技术改进、3D 列印提供精确剂量和防止副作用的潜力以及对个体化药物日益增长的需求是推动 3D 列印药物市场成长的主要因素。 3D列印技术成本高以及3D列印药品难以获得监管机构批准是阻碍3D列印药品产业发展的主要问题。 3D列印药物市场存在一些障碍，例如需要更多的研究和开发以确保这些产品的功效和安全性、标准化3D列印程序的要求以及可能出现的智慧财产权问题。新颖和创造性药物组合物的创造、市场向新地理区域的增长以及 3D 列印彻底改变个人化医疗和药物输送的可能性都是 3D 列印药品市场的机会。对于製药公司来说，在药品製造中使用 3D 列印技术可以开闢新的收入来源。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

Aprecia Pharmaceuticals - (US)
FabRx - (UK)
GlaxoSmithKline - (UK)
Pfizer - (US)
Merck - (US)
Sanofi - (France)
3D Systems - (US)
BASF - (Germany)
Teva Pharmaceuticals - (Israel)
Novartis - (Switzerland)
Roche - (Switzerland)
Catalent - (US)
Johnson & Johnson - (US)
Vertex Pharmaceuticals - (US)
Boehringer Ingelheim - (Germany)
Siemens Healthineers - (Germany)
Sandoz International - (Germany)
BioBots - (US)
Apium Additive Technologies - (Germany)
Boston Micro Fabrication - (US)

简介目录

Product Code: SQMIG35I2140

Global 3D Printed Drugs Market size was valued at USD 84.91 Million in 2022 and is poised to grow from USD 98.5 Million in 2023 to USD 322.91 Million by 2031, at a CAGR of 16% during the forecast period (2024-2031).

Within the pharmaceutical industry, the 3D printed drug market is expanding quickly on a global scale. A growing number of pharmaceutical formulations can be made to order using 3D printing technology, which can increase medication efficacy, lessen side effects, and offer individualized dosage. The method of 3D printing is depositing consecutive layers of material to create a three-dimensional object. In the context of drug production, this entails printing exact medication dosages onto a substrate. The market is dominated by North America, Europe, and Asia Pacific. The market's expansion can be ascribed to the rising need for customized medications, technological improvements, and 3D printing's capacity to deliver accurate dosage and minimize negative effects. The market for 3D printed medications aims to offer a fresh and inventive approach to producing medications that might enhance patient outcomes and lower medical expenses. Drugs may be produced on demand, with less waste and more design freedom thanks to the use of 3D printing technology in medication manufacturing. The need to lower healthcare costs, technological improvements, the potential of 3D printing to deliver exact dosing and prevent side effects, and the growing need for individualized medications are the main factors propelling the growth of the 3D printed drugs market. The high cost of 3D printing technology and the difficulties in getting 3D printed drug approval from regulatory bodies are the main issues impeding the growth of the 3D printed drug industry. The market for 3D printed medications has several obstacles, such as the requirement for more research and development to guarantee the efficacy and safety of these products, the requirement to standardize 3D printing procedures, and the possibility of intellectual property issues. The creation of novel and inventive medication compositions, the market's growth into new geographic areas, and the possibility for 3D printing to revolutionize personalized medicine and drug delivery are among the opportunities in the 3D printed pharmaceuticals market. For pharmaceutical businesses, the use of 3D printing technology in drug manufacture could open up new revenue sources.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global 3D Printed Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global 3D Printed Drugs Market Segmental Analysis

The global 3D printed drugs market is segmented on the basis of product, application, and region. By technology, the market is segmented into inkjet printing, fused deposition modeling, stereolithography, zipdose technology. By application, the market is segmented into orthopedic, neurology, dental, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global 3D Printed Drugs Market

The global market for 3D printed drugs is mostly driven by the rising need for customized medications. Medications that are customized for each patient based on their genetics, lifestyle, and surroundings are known as personalized medicines. Compared to conventional medications, these medications provide a number of benefits, including as greater efficacy, fewer side effects, and higher patient compliance. 3D printing technology is perfect for producing tailored pharmaceuticals since it allows the fabrication of unique drug compositions with accurate dosing and drug release characteristics. Pharmaceutical businesses can now produce medications with distinctive formulas and geometries that are not possible with conventional manufacturing techniques thanks to 3D printing. The necessity for focused drug administration and the growing incidence of chronic diseases are driving up demand for personalized medicines. Long-term care is necessary for chronic conditions like cancer, diabetes, and cardiovascular disease, and individualized medication can enhance patient outcomes and quality of life. Targeted medication administration can also lower the dosage needed, which will lessen adverse effects and increase patient compliance. The market for 3D printed medications is anticipated to expand rapidly in the upcoming years. Global demand for 3D printed drugs is predicted to rise quickly due to the growing need for customized medications and technological developments in this field.

Restraints in the Global 3D Printed Drugs Market

The substantial upfront costs associated with 3D printing hardware, software, and supplies make it challenging for small and medium-sized pharmaceutical enterprises to implement the technology. Because of the high cost of materials and the length of time needed for production, 3D printed medications may have a greater cost per unit than conventional pharmaceuticals. This may result in patients finding 3D printed medications less affordable, which would lower demand for the goods. The regulatory landscape surrounding 3D printed medications is continuously evolving, and obtaining regulatory approval can be a costly and time-consuming procedure. This may further drive up the price of 3D printed medications and restrict patient access to them.

Market Trends of the Global 3D Printed Drugs Market

Pharmaceutical businesses working together with 3D printing companies: In the global market for 3D printed drugs, partnerships between pharmaceutical corporations and 3D printing companies are become more frequent. This partnership is spurring industry innovation and accelerating the release of novel medications and drug delivery technologies. To create innovative medications and drug delivery systems, pharmaceutical companies are collaborating with 3D printing businesses. The manufacture of intricate medication formulations and customized medications with exact dosage and customized formulas is made possible by 3D printing technology. Innovation in the global market for 3D printed drugs is being driven by partnerships between pharmaceutical companies and 3D printing enterprises. This partnership is accelerating the release of new medications and drug delivery technologies, and it is anticipated to sustain industry expansion in the years to come.

Positive government initiatives: The global market for 3D printed drugs is expanding thanks in large part to positive government initiatives. Globally, numerous governments are launching programs to encourage the advancement and application of 3D printing technology in the medical field. These programs are promoting market expansion and assisting in the development of a regulatory framework that is favorable to the sector. Positive government actions are a major factor in the global market for 3D printed drugs' expansion. These programs include fostering innovation, advancing the development of novel medications and drug delivery technologies, and assisting in the establishment of a regulatory environment that is favorable to the sector.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global 3D Printed Drugs Market by Technology Type

Market Overview
Inkjet Printing
Fused Deposition Modeling
Stereolithography
and Zip Dose Technology

Global 3D Printed Drugs Market by Application

Market Overview
Orthopaedic
Neurology
Dental
and Others

Global 3D Printed Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Aprecia Pharmaceuticals - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FabRx - (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline - (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi - (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
3D Systems - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BASF - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals - (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis - (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche - (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioBots - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apium Additive Technologies - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Micro Fabrication - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments